Implante valvular aórtico transarterial: experiencia en Chile / Transcatheter aortic valve implantation: Experience in 17 patients

Background: Transcatheter aortic valve implantation (TAVI) is taking a leading role in the management of patients with severe aortic stenosis. Valve replacement surgery prolongs survival and is the technique of choice considering its historical background and long experience worldwide. Recently however, TAVI has positioned itself as the only standard therapy for symptomatic patients who are not candidates for surgery. Aim: To report the experience with this new technique comparing our results with those reported in the literature. Material and Methods: Between May 2010 and December 2011,17patients aged 81 ± 7.3 years (58.8% men with an Euro SCORE 29 ± 22.4%) underwent a TAVI. Results: The median transvalvular gradient was 54 ± 15.7 mmHg. All patients received a CoreValveTM. Technical success was 100%, with a post implant gradient of 6.29 ± 3.3 mmHg. Residual aortic regurgita-tion was observed in 94%, none greater than grade II. There were no complications at the vascular access site. One patient developed cardiac tamponade during the procedure. Permanent pacemaker implantation was required in 35.2%. Hospital mortality rate was 5.8%, a figure that remained unchanged at 30 days offollow-up. Conclusions: In high-risk patients with aortic stenosis, TAVI has a high success rate and a low rate of complications. Besides an appropriate patient selection, a trained multidisciplinary team and technical conditions to solve possible complications of the procedure are required.

Operação de Bentall e De Bono para correção das doenças da raiz aórtica: análise de resultados a longo prazo / Bentall and De Bono surgery for correction of valve and ascending aortic disease: long-term results

OBJETIVO: Um estudo retrospectivo foi desenhado tendo como fator de inclusão a cirurgia de Bentall e De Bono. MÉTODOS: Dados foram retirados de prontuários médicos e informações de seguimento a longo prazo obtidas por meio de retornos ambulatoriais e contatos diretos com o paciente. Trinta e nove pacientes foram acompanhados no período de janeiro de 1996 a dezembro de 2005. RESULTADOS: A mediana de idade foi 47 anos, sendo 85 por cento dos pacientes do sexo masculino. Onze (25,5 por cento) pacientes apresentavam síndrome de Marfan e um (2,5 por cento) síndrome de Turner. Entre os fatores de risco, listaram-se: hipertensão em 19 (48,5 por cento) pacientes, tabagismo em oito (20,5 por cento), etilismo em seis (15,5 por cento), dislipidemia em oito (20,5 por cento), diabetes melito em dois (5 por cento) e presença de IAM prévio em um (2,5 por cento). Vinte e oito (72 por cento) pacientes estavam em classe II-III NYHA ao momento da operação. Ectasia ânulo-aórtica era diagnóstico em 14 (36 por cento) pacientes e aneurisma da aorta em 16 (41 por cento). O tempo médio de permanência na UTI foi 8,8 dias, com intervalo de 2-23 dias. A taxa de sobrevida em 30 dias (intra-hospitalar) foi de 94,87 por cento (2/39). Em um ano, 37 (94,87 por cento) pacientes estavam vivos, e em 5 e 10 anos, 33 (84,61 por cento). O tempo de acompanhamento médio foi de 46,5 meses, com intervalo de 14-120 meses. CONCLUSÃO: A técnica descrita por Bentall e De Bono obteve excelentes resultados a curto e longo prazo, sendo eficaz e segura no tratamento de doenças da valva aórtica e aorta ascendente em nosso serviço. Nossos resultados são condizentes com dados atuais da literatura.

OBJECTIVE: A retrospective study was perfomed in a series of consecutive patients who underwent a Bentall and De Bono procedure. Methods: Data were removed of medical records and follow-up data were obtained from clinical records and direct contact with patients. A total of 39 patients were studied between January 1996 and December 2005. RESULTS: The median age was 47 years (range 14-70). There were 33 males and six females. Eleven (25.5 percent) patients presented Marfan syndrome and one (2.5 percent) Turner syndrome. Nineteen (48.5 percent) patients had hypertension, eight (20.5 percent) had history of smoking, six (15.5 percent) had history of alcoholism, eight (20.5 percent) had dyslipidemia, two (5.0 percent) had diabetes and one (2.56 percent) had myocardial infarct previously. Twenty-eight (72 percent) patients were in II-III NYHA class in the moment of the surgery. Annulo-aortic ectasy was present in 14 (35.9 percent) patients and aortic aneuryms in 16 (41 percent). The median time in intensive care unit was 8.79 days with range 2-23 days. Four (10.0 percent) patients underwent an emergency opertation and 35 (90 percent) elective. The overall hospital mortality was 5 percent (2/39). The event-free survival is 94.87 percent at 1 year and 84.61 percent at in 5 and 10. The median time of follow-up was 46.5 months (range 14-120 months). CONCLUSION: The Bentall and De Bono technique obtained excellent results in the short-term and long-term, which support the continued use of the compositive graft technique as the preferred method of treatament for patients with aortic root disease. Our findings confirm the current literature data.

Resultados alejados de la reparación versus reemplazo en insuficiencia mitral degenerativa / Long-term results of repair versus replacement for degenerative mitral valve regurgitation

Background: Mitral valve repair is considered better than mitral valve replacement for degenerative mitral regurgitation. Aim: To evaluate late clinical results of mitral valve repair as compared to mitral valve replacement in patients with degenerative mitral regurgitation. Patients and methods: All patients subjected to open heart surgery for degenerative mitral regurgitation between 1990 and 2002 were assessed for surgical mortality, late cardiac and overall mortality, reoperation, readmission to hospital, functional capacity and anticoagulant therapy. Eighty eight patients (48 males) had mitral valve repair and 28 (19 males) had mitral valve replacement (23 with a mechanical prosthesis). Mean age was 59.9 ± 14.8 (SD) and 61.3 ± 14.6 years, respectively. Sixty three percent of patients with repair and 50% of those with valve replacement were in functional class III or IV before surgery. Results: Operative mortality was 2.3% for mitral valve repair and 3.6% for mitral valve replacement (NS). Also, there was no statistical difference in the need of reoperation during the follow-up period between both procedures (2.3% and 0%, respectively). Ninety four percent of the replacement patients but only 26% of the repair patients were in anticoagulant therapy at the end of the follow-up period (p <0.001). Ten years survival rates were 82 ± 6% for mitral valve repair and 54 ± 11% for replacement. The corresponding cardiac related survival rates were 89 ± 6% and 79 ± 10%. At the end of follow-up, all surviving patients were in functional class I or II. Ten years freedom from cardiac event rates (death, cardiac related rehospitalization and reoperation) were 90 ± 3% for mitral valve repair and 84 ± 6% for replacement. Conclusion: Repair of the mitral valve offers a better overall survival and a better chance of freedom from cardiac events as well as need for anticoagulation 10 years after surgery.